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Abstract
The prevalence of hepatopulmonary syndrome (HPS) in the setting of cirrhosis ranges 
between 4 and 47% and its presence increases the mortality rate, especially when hypox‐
emia is present. Our study aim was to fix whether there is a correlation of results between 
two simple and non‐invasive procedures such as transthoracic contrast‐enhanced ultra‐
sound (CEUS) and pulse oximetry, used for early detection of HPS in patients with liver 
cirrhosis, having as endpoint the improvement in their outcome. The rapid lung enhance‐
ment and delayed left ventricle enhancement of the saline solution, after at least three 
systolic beats during CEUS and pulse oximetry showing a SaO
2
 < 95%, were correlated 
and considered positive for the diagnosis of HPS. One hundred and sixty‐five (44%) of 
the total of 375 patients diagnosed with liver cirrhosis enrolled in the current study, with 
or without respiratory symptoms (dyspnea, clubbing, distal cyanosis, cough and/or spi‐
der angioma), showed positive criteria for HPS diagnosis during CEUS. SaO
2
 < 95% and 
PaO
2
 < 70 mmHg were found in 123 patients (33%) during pulse oximetry investigation. 
Pearson correlation index showed a good correlation between lung and heart CEUS find‐
ings and pulse oximetry (r = 0.97) for HPS diagnosis. CEUS and pulse oximetry results 
correlate and rapidly diagnose HPS, a highly fatal complication of liver cirrhosis (LC), 
guiding the future treatment by speeding up orthotopic liver transplant OLT recommen‐
dations to improve the survival rates.
Keywords: transthoracic contrast‐enhanced ultrasonography, pulse oximetry, liver 
cirrhosis, hepatopulmonary syndrome, hypoxemia
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1. Introduction
The hepatopulmonary syndrome (HPS) represents a complication of liver cirrhosis character‐
ized by a gross dilatation of the pulmonary precapillary and capillary vessels, an increase in 
the number of dilated vessels, portopulmonary anastomoses, pleural and pulmonary arterio‐
venous shunts. It can be diagnosed when the triad represented by liver disease, impaired oxy‐
genation and intrapulmonary vascular abnormalities, referred to as intrapulmonary vascular 
dilatations (IPVDs) coexist [1]. The prevalence of pulmonary complications associated with 
liver cirrhosis ranges between 4 and 47%, worsening the evolution and prognosis, especially 
when hypoxemia is present [2, 3]. According to the medical literature focused on the current 
topic, 23% of patients with HPS have an average survival rate around 24 months, compared 
to 63% of patients without HPS. Survival can be further worsened in case of comorbidities 
or advanced age [4]. Respiratory signs and symptoms are common in patients with liver cir‐
rhosis, no matter the stage of the disease. Intrapulmonary vascular complications of liver cir‐
rhosis consist of hepatopulmonary syndrome (HPS) and portopulmonary hypertension. HPS 
appears when intrapulmonary blood shunting impairs arterial gas exchange [5], and por‐
topulmonary hypertension occurs when pulmonary arterial constriction leads to increased 
pulmonary arterial pressure [6]. The latter, although rare, can cause pulmonary complication, 
which worsens the morbidity and mortality in patients with liver dysfunction. The outcome of 
patients with advanced liver disease, complicated with pulmonary involvement, can be influ‐
enced even in the setting of orthotopic liver transplant, due to chronic hypoxemia installed 
during the evolution of cirrhosis influencing the prognosis. A key factor in the diagnosis of 
HPS is the exclusion of causes other than HPS that may be involved in cirrhosis and charac‐
terized by hypoxemia (cardiopulmonary abnormalities, pulmonary atelectasis, pneumonia, 
ascites, pulmonary edema or hepatic hydrothorax) [7]. The challenge for physicians working 
in the field of hepatology is to raise the idea of establishing new methods for a conventional, 
rapid and simple diagnosis of pulmonary involvement during the evolution of liver cirrhosis, 
in order to improve as much as possible the outcome of possible curative treatment.
HPS is defined by a widened alveolar‐arterial oxygen gradient (age corrected) in room air, 
with or without hypoxemia. It results from intrapulmonary vascular dilatations in the pres‐
ence of hepatic dysfunction and/or portal hypertension [8, 9].
The development of pulmonary vascular dilatation has as pathogenic mechanism a pulmo‐
nary overproduction of endogenous nitric oxide (NO) [10]. According to studies focused on 
the topic in the last two decades, a theory can be formulated according to which endothelin‐1 
and tumor necrosis factor‐α may play a role in pulmonary microvascular tone modulation 
[11, 12]. The contributing factors to the process of pulmonary microvascular dilatation in HPS 
include angiogenesis, vascular remodeling, pulmonary arteriovenous shunts and portopul‐
monary venous anastomoses [13, 14].
Trough this pathogenic mechanism, the rapid or direct passage of mixed venous blood into 
the pulmonary veins is responsible for the pulmonary vascular dilatation. The mismatch of 
ventilation‐perfusion sequence produces a deficit in the blood oxygenation. The inhibition of 
hypoxic vasoconstriction produces an increased blood flow and preserved alveolar ventilation. 
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The alveolar‐arterial oxygen tension difference—≥15, or ≥20 mmHg for patients aged >64 is 
considered as a very sensitive index of early arterial deoxygenation in HPS, and this difference 
being overload before arterial oxygen tension becomes abnormally low [8]. On the other hand, 
the alveolar‐capillary interface is too wide to allow for complete equilibration of carbon mon‐
oxide with hemoglobin, thus being translated in reducing the diffusing capacity of the lungs 
for carbon monoxide.
Patients complain of symptoms correlated not only with the subsequent liver disease, but also 
with the respiratory signs and symptoms, usually revealing dyspnea and cyanosis. The man‐
agement of these patients requires the exclusion of other causes for such respiratory symptoms, 
because chronic obstructive pulmonary disease and pulmonary fibrosis can coexist in approxi‐
mately 30% of patients with HPS [15]. Dyspnea (“platypnea”) and hypoxemia (“orthodeoxia”) 
are characteristically worsened in the upright position and improved by lying supine, result‐
ing from a gravitational increase in blood flow through dilated vessels in the lung bases [16].
According to the pathogenic definition, the diagnosis of HPS requires evidence of pulmo‐
nary vascular dilatation and hypoxemia, with no cardiopulmonary disease history. To stage 
the severity of the disease, it is required to investigate the arterial blood gas tension at rest, 
while breathing room air and in the sitting position. A sensitive and non‐invasive tool for the 
detection of pulmonary vascular dilatation is the contrast‐enhanced transthoracic echocar‐
diography after injection of hand‐agitated normal saline. During the first pass, microbubbles 
are physiologically trapped and absorbed by alveoli, and they should not be seen in the left 
atrium. The passage of saline microbubbles through abnormally dilated lung vessels requires 
more than three cardiac cycles to reach left heart chambers [17]. In contrast, the immediate 
enhancement of saline microbubbles in the left atrium raises the suspicion of an intracar‐
diac right‐to‐left shunt [18]. The alternative to CEUS investigation is scintigraphic perfusion 
scanning, which uses the technetium‐99‐labeled albumin macroaggregates >20 μm in diam‐
eter. The uptake of tc‐99‐labeled albumin macroaggregated in other organs occurs in case of 
right‐to‐left shunt, while the trapping of albumin macroaggregates in pulmonary circulation 
is characteristic for HPS [19].
The present management of HPS lacks of efficient therapy solutions, until the OLT is avail‐
able. Starting from the pathogenic mechanism, physicians investigated several classes of 
drugs such as β‐blockers, cyclo‐oxygenase inhibitors, systemic corticosteroids, cyclophospha‐
mide, inhaled NO, and NO inhibitors, but without a real benefit in oxygenation improve‐
ment or pulmonary vascular dilatation. The only efficient treatment in case of severe and 
refractory hypoxemia is the oxygen supplementation, with complete resolution in more than 
80%, according to study results [8, 20]. The presence of HPS offers exception points in MELD 
scoring and an advantage for patients to occupy better places on waiting lists for OLT [21]. 
Without OLT, the prognosis for HPS is poor, with mortality around 41% of patients over a 
mean period of 2.5 years [22]. The literature data do not provide reliable clinical predictors or 
diagnosis guidelines for the outcome of HPS [23].
A retrospective cohort analysis of data submitted to the United Network for Organ Sharing 
studied the effects of room‐air oxygenation of patients with HPS and the pre‐ and post‐trans‐
plantation outcomes. Patients with HPS were given MELD exception points and prioritized 
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for liver transplantation due to their high pre‐ and post‐transplantation mortality. Comparing 
the overall survival rates of patients with and without HPS, transplant recipients with more 
severe hypoxemia had increased risk of death after liver transplantation. The overall mortality 
was significantly lower among waitlist candidates with HPS (hazard ratio = 0.82; 95% CI: 0.70–
0.96), having the OLT before the deterioration of tissue oxygenation and liver dysfunction, due 
to exception MELD points given, which provided an advantage for a rapid transplant [24].
The aim of our study was a possible correlation between contrast‐enhanced ultrasound 
(CEUS) findings on heart and pulse oximetry, in order to early detect HPS, as a prognostic 
factor for orthotopic liver transplant (OLT) success [25].
2. Methods
Demographic data, etiology and severity scores were recorded. For the diagnosis of HPS, 
we used the classical triad: presence of chronic liver disease, an increased alveolar‐arterial 
oxygen gradient, and evidence of right‐to‐left intrapulmonary shunt (IPS) [26]. In order 
to determine the HPS diagnosis, we used the classical charts provided by the guidelines 
for transplant candidates (Table 1). The diagnosis of liver cirrhosis was based on clini‐
cal, biochemical, ultrasound, and upper endoscopy criteria. The patients with liver cir‐
rhosis were classified according to MELD scores, considering exception points according 
to international recommendations. The contrast‐enhanced echocardiography (CEUS) [27], 
technetium‐99m‐labeled macroaggregated albumin (Tc‐99m MAA) scanning [28], and 
pulmonary arteriography are the current imagistic tools to diagnose the IPS. We corre‐
lated transthoracic CEUS findings with pulse oxymetry as a screening test for detecting 
IPS in 375 patients diagnosed with liver cirrhosis between December 2009 and June 2016 
in Gastroenterology Department of Clinical Emergency Hospital “St Apostle Andrew” of 
Constanta County.
Criteria Data requirements
Strict HPS criteria Alveolar‐arterial gradient ≥15 mmHg, or ≥20 mmHg if age older than 
60 years
Intrapulmonary shunting on transthoracic echocardiogram or >6% shunt 
fraction on macroaggregated albumin scan
No evidence of severe restrictive or obstructive pulmonary disease
Hypoxia/hypoxemia+ IP shunts Hypoxemia defined as:
• PaO
2
 <70 mmHg on room air or
• Pulse oximetry ≤96% (room air or supplemental O
2
)
Intrapulmonary shunting (right → left bubbles on echocardiogram after 
three cardiac cycles and/or free text stating “intrapulmonary shunting”)
No evidence of concurrent cardiopulmonary disease
Table 1. Inclusion criteria defining OLT waitlist candidates with HPS based on exception narrative data [28].
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All patients were examined by chest X‐ray and pulmonary function tests (to rule out common 
intrinsic pulmonary disorders such as chronic obstructive pulmonary disease). We used as a 
contrast agent of hand‐agitated saline solution, in order to produce microbubbles with a mean 
diameter of up to 10 μm injected through a peripheral vein. Unlike blood, microbubbles reso‐
nate at a frequency similar to clinical transducer frequencies, which make ultrasounds to be 
reflected. Under normal circumstances, only the right heart chambers are opacified, and the 
microbubbles are trapped in the pulmonary capillaries (mean diameter, 8 μm). The presence 
of contrast in the left chamber suggests an arteriovenous connection. In patients with intra‐
cardiac shunts, a small amount of contrast is usually recorded in the left chambers within 1 or 
2 cardiac cycles after its appearance in the right‐side chambers (early shunt). On the contrary, 
late arrival of contrast in the left atrium after a time delay of 4–8 cardiac cycles is diagnostic 
for HPS (delayed shunt) and is done by the time required for passage through the pulmonary 
circulation [27]. Measurement of SaO
2
 was performed with a portable pulse oximeter. In all 
patients, the measurements were performed at ambient O
2
 partial pressure in supine position. 
We have chosen a SaO
2
 value of <95% in order to detect all HPS patients with a PaO
2
 < 70. The 
correlation of rapid lung enhancement and delayed left ventricle enhancement of the saline 
solution, after at least three systolic beats in the left ventricle during CEUS and pulse oximetry 
showing a SaO
2
 < 95% was considered positive for the diagnosis of HPS [29].
3. Results
A total of 375 patients diagnosed with liver cirrhosis were enrolled in our study. The majority 
of patients were male (251/375). The average age was 66.04 years (SD 8.81). The etiology of liver 
cirrhosis was alcohol abuse in 39% (146/375) of patients, viral hepatitis B (VHB) in 28% (105/375) 
of patients, viral hepatitis C (VHC) in 21% (79/375) of patients, and the rest of 12% (45/375) hav‐
ing uncommon etiologies. Severity in MELD score divided our patients in three groups accord‐
ing to which we could fix the prognosis and the need of transplantation (Table 2).
According to present international recommendations, we decided upon exception points 
for those patients meeting the criteria for MELD exception: patients with PaO
2
 < 60 mmHg 
on room air at rest in the sitting position, arterial blood gas result provided, patients with 
pulmonary vascular dilatation documented by a positive transthoracic contrast echocardiog‐
raphy, patients with absence of significant alternative pulmonary disease to explain severe 
hypoxemia (chest X‐ray, pulmonary function tests, and chest computed tomography reports), 
patients with moderate or severe pulmonary function tests changes or significant chest X‐ray 
abnormalities or MAA scan positive for intrapulmonary shunting) (Table 3). From the total 
of 375 patients studied, 165 (44%) presented respiratory symptoms. Pulse oximetry showed 
alterations, such as SaO
2
 < 95% and PaO
2
 < 70 mmHg in 123 patients (33%). From 375 patients 
diagnosed with LC, with or without present respiratory signs and/or symptoms (dyspnea, 
clubbing, distal cyanosis, cough and/or spider angioma) referred to CEUS examination, 105 
(28%) had rapid lung enhancement and delayed left ventricle enhancement of the contrast 
agent (Figures 1–3). PaO
2
 was less than 70 mmHg in all 105 HPS patients (100%) versus 12 
(14.76%) of non‐HPS patients (P < 0.0001). Pearson correlation index showed a good correla‐
tion between lung and heart CEUS findings and pulse oximetry (r = 0.97) in HPS diagnosis.
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Variable HPS (no, %) Non‐HPS (no, %)
 Mean age (IQR) 66.04 ± 8.81 (95% CI, 58.44–74.85) 63.10 ± 10.71 (95% CI, 61.55–64.65)
Gender
Males 128 (50.99) 123 (49.00)
Females 59 (47.58) 65 (52.41)
Race
Caucasians 92 (87.61) 243 (90)
Blacks 2 (1.90) 1 (0.37)
Asians 11 (10.47) 26 (09.62)
Ethnicity
Romanian 51 (48.57) 173 (64.07)
Turcs/tatars 8 (7.61) 19 (7.03)
Moldavians 4 (3.80) 9 (3.33)
Macedonians 31 (29.52) 42 (15.55)
Other 11 (10.47) 27 (10)
Primary diagnosis
HCV 27 (25.71) 52 (19.25)
HBV 31 (29.52) 74 (27.40)
Alcohol 39 (37.14) 106 (39.25)
HVD 5 (4.76) 18 (6.66)
Autoimmune 2 (1.90) 4 (1.48)
NASH/criptogenetic 1 (0.95) 9 (3.33)
Other rare causes – 5 (1.85)
MELD score, median (IQR) 14 (11–22) 16 (11–24)
MELD score categories
<15 47 (44.76) 156 (57.77)
15–20 34 (32.38) 76 (28.14)




 < 60 mmHG (22 pts) 5 (4.76) –
PaO
2
 = 51–55 mmHG (24 pts) 4 (3.80) –
PaO
2
 < 50 mmHG (26 pts) 1 (00.95 –
History of ascites 84 (80.00) 229 (84.81)
History of liver decompensations 74 (70.47) 172 (63.70)
Table 2. Baseline clinical and demographic characteristics of HPS and non‐HPS patients.
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PaO
2
Exception points for MELD scoring for HPS
56–59 mmHg 22 MELD points
51–55 mmHg 24 MELD points
<50 mmHg 26 MELD points
Table 3. Allocation of exception points for HPS in MELD scoring system [28].
Figure 1. Contrast‐enhanced echocardiogram. Apical four‐chamber view before contrast injection.
Figure 2. Contrast‐enhanced echocardiogram. Apical four‐chamber view after contrast injection (agitated saline) 
showing the presence of bubbles in the right chambers and no bubbles in the left chambers after the first sistola.




HPS was defined as a triad of portal hypertension with or without hepatic dysfunction, intra‐
pulmonary vascular dilatation or shunting, and hypoxemia [30]. Hypoxemia was defined by 
PaO
2
 cutoff level of less than 70 mmHg in an arterial blood sample to pick up these patients 
for further evaluation by CEUS. This arterial PO
2
 cutoff level was suggested by previous 
researchers [31], who found that patients with PaO
2
 of more than 70 mmHg were unlikely to 
have HPS.
In the current study, among 375 patients diagnosed with liver cirrhosis, 105 patients (28%) 
met the clinical, laboratory and imagistic criteria of HPS. HPS shows a wide variability in 
prevalence in different studies, ranging from 4 to 47% among cirrhotic patients [1, 4, 32], 
depending on the diagnostic criteria and the cutoff levels used for hypoxia. In our study, 
PaO
2
 was less than 70 mmHg in 100% of HPS patients versus 12% of non‐HPS patients, in 
which pulmonary function tests were used to diagnose chronic intrinsic pulmonary disease. 
All patients with positive CEUS findings had arterial PaO
2
<70 mmHg and were qualified for 
the diagnosis of HPS. CEUS was proved by previous investigators to be a useful sensitive and 
specific screening test for HPS even in early stages of liver dysfunction and even in whom 
the lung scintigraphy was still negative [33]. Some authors suggested transesophageal CEUS 
as a gold standard [34, 35]. However, others argued that transthoracic CEUS has the same 
accuracy as transesophageal CEUS in determining the presence of right to left shunt. Proper 
timing of left atrial opacification by microbubbles during the cardiac cycle was considered 
a distinguishing step in the transthoracic CEUS between intracardiac and intrapulmonary 
shunting [36]. Transesophageal CEUS might have higher sensitivity than transthoracic CEUS 
Figure 3. Contrast‐enhanced echocardiogram. Apical four‐chamber view after contrast injection (agitated saline) 
showing the presence of bubbles in the right heart chambers and the appearance of bubbles in the left heart chambers, 
late, after the forth sistola.
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because it allows the contrast to be seen when entering from the pulmonary veins [37, 38]. 
However, transthoracic CEUS is diagnostic in the majority of cases. In addition, esophageal 
varices are relatively common in these patients, and this can be considered as a relative con‐
traindication in transesophageal CEUS performing [29, 39].
According to their correlated results, the transthoracic CEUS and pulse oximetry could be 
inserted in the algorithm of liver cirrhosis staging, in order to select those patients in need 
for a more rapid indication of OLT. Both methods provide data regarding the pulmonary 
dysfunction during liver cirrhosis evolution, improving the outcome after OLT, especially in 
HPS patients with moderate or severe hypoxemia. The presymptomatic stage of HPS can be 
correctly diagnosed using the combination of these two methods, making the algorithm of 
liver cirrhosis staging more accurate.
5. Conclusion
Our study showed a good correlation between lung and heart CEUS findings and pulse oxim‐
etry in HPS diagnosis. When correlated, these two simple, non‐invasive, low‐cost and rapid 
methods can easily diagnose HPS, a highly fatal complication of liver cirrhosis, which can 
worsen the outcome of patients even after OLT.
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